Ascletis Pharma Inc. (1672.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In HKD
Address
12th Floor, Block D, Hangzhou Bay Information Port, Number 198 Qidi Road, Xiaoshan District
Hangzhou, ZH 311200
China
Phone
86 571 8538 9730
Website
Sector
Healthcare
Industry
Biotechnology
Employees
202
First IPO Date
August 01, 2018
| Name | Title | Pay | Year Born |
| Jinzi Wu | Founder, Chairman & Chief Executive Officer | 119.04M | 1963 |
| Hejingdao Wu | Senior Vice President of Operations & Executive Director | 7.24M | 1974 |
| Ming Fai Chung | Company Secretary | 0 | 1979 |
| George Zhengzhi Hill | Senior Consultant & Chief Medical Advisor | 0 | 1951 |
| Kristjan Sigurdur Gudmundsson | Senior Consultant & Head of Discovery | 0 | 1968 |
| John Gargiulo | Chief Business Officer | 0 | 1960 |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.